These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33660954)

  • 21. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China).
    Fan JG; Wei L; Zhuang H;
    J Dig Dis; 2019 Apr; 20(4):163-173. PubMed ID: 30444584
    [No Abstract]   [Full Text] [Related]  

  • 22. Non-Invasive Diagnosis of Nonalcoholic Fatty Liver Disease.
    Yoneda M; Imajo K; Nakajima A
    Am J Gastroenterol; 2018 May; 113(10):1409-1411. PubMed ID: 29937542
    [No Abstract]   [Full Text] [Related]  

  • 23. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt.
    Alkassabany YM; Farghaly AG; El-Ghitany EM
    Arab J Gastroenterol; 2014 Jun; 15(2):76-81. PubMed ID: 25097051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-alcoholic fatty liver disease: A growing public health problem in Turkey.
    Kaya E; Yılmaz Y
    Turk J Gastroenterol; 2019 Oct; 30(10):865-871. PubMed ID: 31258135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonalcoholic Fatty Liver Disease.
    Filipović B; Forbes A; Tepeš B; Dumitraşcu DL
    Can J Gastroenterol Hepatol; 2018; 2018():2097435. PubMed ID: 30155450
    [No Abstract]   [Full Text] [Related]  

  • 26. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).
    Vos MB; Abrams SH; Barlow SE; Caprio S; Daniels SR; Kohli R; Mouzaki M; Sathya P; Schwimmer JB; Sundaram SS; Xanthakos SA
    J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):319-334. PubMed ID: 28107283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Strengthen researches on risk factors and early diagnosis of nonalcoholic fatty liver].
    Li YM
    Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):805-7. PubMed ID: 24516924
    [No Abstract]   [Full Text] [Related]  

  • 28. How to Approach a Patient With Nonalcoholic Fatty Liver Disease.
    Tilg H
    Gastroenterology; 2017 Aug; 153(2):345-349. PubMed ID: 28647352
    [No Abstract]   [Full Text] [Related]  

  • 29. [Pathogenesis of non-alcoholic fatty liver disease].
    Anty R; Gual P
    Presse Med; 2019 Dec; 48(12):1468-1483. PubMed ID: 31767252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease.
    Cotter TG; Rinella M
    Gastroenterology; 2020 May; 158(7):1851-1864. PubMed ID: 32061595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An update on nonalcoholic fatty liver disease.
    Provencher DM
    JAAPA; 2014 Jul; 27(7):18-22. PubMed ID: 24901731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Advances in epidemiology and serum markers for the noninvasive diagnosis of nonalcoholic fatty liver disease].
    Feng G; He N; Wang JN; Mi M; Niu CY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Jun; 26(6):476-480. PubMed ID: 30317767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
    Chalasani N; Younossi Z; Lavine JE; Charlton M; Cusi K; Rinella M; Harrison SA; Brunt EM; Sanyal AJ
    Hepatology; 2018 Jan; 67(1):328-357. PubMed ID: 28714183
    [No Abstract]   [Full Text] [Related]  

  • 35. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.
    Shaheen AA; Riazi K; Medellin A; Bhayana D; Kaplan GG; Jiang J; Park R; Schaufert W; Burak KW; Sargious M; Swain MG
    CMAJ Open; 2020; 8(2):E370-E376. PubMed ID: 32414883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Moderate Alcohol Drinking in Patients with Nonalcoholic Fatty Liver Disease.
    Kwon I; Jun DW; Moon JH
    Gut Liver; 2019 May; 13(3):308-314. PubMed ID: 30400736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Spengler EK; Loomba R
    Mayo Clin Proc; 2015 Sep; 90(9):1233-46. PubMed ID: 26219858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-alcoholic fatty liver disease: A poorly known pandemic.
    Augustin S; Graupera I; Caballeria J;
    Med Clin (Barc); 2017 Dec; 149(12):542-548. PubMed ID: 28751080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation.
    Kappus M; Abdelmalek M
    Clin Liver Dis; 2017 May; 21(2):321-335. PubMed ID: 28364816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonalcoholic fatty liver disease: Evolving paradigms.
    Lonardo A; Nascimbeni F; Maurantonio M; Marrazzo A; Rinaldi L; Adinolfi LE
    World J Gastroenterol; 2017 Sep; 23(36):6571-6592. PubMed ID: 29085206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.